Navigation Links
First Patients Enrolled in Phase II Trial With Intravenous Iclaprim in HAP/VAP/HCAP
Date:12/12/2007

setting. AR-709 exhibited potent activity against a large panel of pneumococcal clinical isolates including those resistant to currently used drugs. Promising results of "first-in-man" studies with AR-709 were published in March 2007.

An additional compound, AR-2474, has achieved in vivo proof of concept. AR-2474 has been shown to be highly effective in eradicating pathogens in preclinical models of skin infection and nasal carriage.

Apart from the antibiotic programmes, Arpida has an innovative antifungal therapy (TLT) which is about to enter Phase III clinical trials in Europe, targeting onychomycosis.

Moreover, the company has several other leads in optimisation and additional discovery programmes derived from its own discovery platform at various research stages.

This press release contains specific forward-looking statements, e.g. statements including terms like believe, assume, expect or similar expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties and other factors which may result in a substantial divergence between the actual results, financial situation, development or performance of the company and those explicitly or implicitly presumed in these statements. Against the background of these uncertainties readers should not place undue reliance on forward-looking statements. The company assumes no responsibility to update forward-looking statements or to adapt them to future events or developments.

Arpida contacts:

Dr Khalid Islam, President and CEO Tel: +41-61-417-96-60

Harry Welten, MBA, CFO and Senior Vice President Tel: +41-61-417-96-65

Paul Verbraeken, Head of Corporate Communications Tel: +41-61-417-96-83


'/>"/>
SOURCE Arpida Ltd
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Reclast(R) Receives US FDA Approval as First and Only Once-Yearly Treatment for Women With Postmenopausal Osteoporosis
2. GlaxoSmithKline Recognizes University of Michigans Dr. Daniel F. Hayes as the First Recipient of the Gianni Bonadonna Breast Cancer Award
3. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
4. Genmab Announces 2007 First Half Year Results
5. Pharsight Achieves First License Sale for Public-Source Database
6. Novare Announces First Ever Single Port Laparoscopic Kidney Removal (Nephrectomy) Using RealHand(TM) HD Instruments
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. China Medical Technologies Reports First Quarter Financial Results
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
11. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/19/2009)...EW YORK, Nov. 19 NeoStem... has sent the following letter to its shareholders... 30, 2009, of China Biopharmaceuticals Holdings, I...ny based in the People,s Republic of China. The me...uzhou Eyre Pharmaceutical Co. Ltd., CHBP,s primary...
(Date:11/19/2009)...ONTREAL, Nov. 19 /PRNewswire/ - Aegera Therapeutic...ient in a randomized Phase 2B study of AEG35156, a...opment for multiple oncology indications. ,, Th...2 Study of the X-Linked Inhibitor of Apoptosis (XI...igh-dose Cytarabine and Idarubicin in AML Followin...
(Date:11/19/2009)..., VIENNA, Austria, November 19 /PRNewswire/ -...ogram on one product candidate at an unexpectedly ...AD02 is planned to enter into,Phase II clinical tr...mediately follows the completion of two Phase I tr...y based its fast decision on the first interim,ana...
(Date:11/18/2009)...N, Ill. Imagine a polka-dotted postage stamp that...mply by changing colors. , As reported in the Se...nneth Suslick and his team at the University of Il...eneral detection of toxic industrial chemicals (TI...s by visualizing odors. This sensor array could b...
Breaking Biology Technology:NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 2NeoStem Outlines to Shareholders Near-term and Long-term Business Strategies Following Acquisition of Chinese Pharmaceutical Company 3Aegera Therapeutics Initiates a Randomized Phase 2B Study with AEG35156 for the Treatment of Acute Myeloid Leukemia (AML) 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 2AFFiRiS AG: Interim Analysis of Clinical Phase I Data Triggered Decision to Move Alzheimer's Vaccine Candidate AD02 into Clinical Phase II Testing 3Opto-electronic nose sniffs out toxic gases 2Opto-electronic nose sniffs out toxic gases 3
... Sept. 18 Ingenuity Systems, the,leading provider...cientific,literature and data, is pleased to annou... major public-private biomedical research,partners...biological,markers to support new drug development...he founding members of the Consortium include the ...
...er 18 - Clinical Study Demonstrates Breakthrough... Capacities and Expands Potential Production,Capac... Sanofi pasteur, the vaccines division of sanofi-...ts new investigational H5N1 pandemic influenza,vac...high immune response,at the lowest dose of H5N1 an...
...e University of Pennsylvania have developed nanowi...ears and retrieving that data a thousand times fas...Flash memory and micro-drives, all using less powe...tesh Agarwal, an assistant professor in the Depart...leagues developed a self-assembling nanowire of ge...
Other Biology Technology:Ingenuity Systems Joins Biomarkers Consortium 2Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 2Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 3Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 4Sanofi Pasteur's Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage 5Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster 2Penn engineers design computer memory in nanoscale form that retrieves data 1,000 times faster 3
(Date:11/20/2009)...te their abstracts to the World Congress on Osteop... meeting devoted to all aspects of osteoporosis an...ngress will be held in Florence, Italy from May 5-...mitted online at http://www.iofwco-ecceo10.org ..., IOF and ESCEO are pleased to announce that seve...
(Date:11/20/2009)...acterial gene into yeast, researchers from Delft U...d three improvements in bioethanol production from...acetate and elimination of the major by-product gl...he scientific journal Applied and Environmental M...e by the yeast Saccharomyces cerevisiae from sugar...
(Date:11/20/2009)... Center (ERC) has been awarded a grant from the U....f recovering and reusing the heat that would be ge...process in a carbon capture system. The goal of th... and sequestration, or storage (CCS), and thus lim...into the atmosphere by coal-fired power plants. ,...
Breaking Biology News(10 mins):Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 2Special sessions announced for World Congress on Osteoporosis 2010 - IOF WCO - ECCEO10 3Delft breakthrough in bioethanol production from agricultural waste 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 2Lehigh receives grant to reduce cost of carbon capture at coal-fired power plants 3Smart For Life 28TM 29 Makes Debut on BJs com 59203 1Smart For Life 28TM 29 Makes Debut on BJs com 59203 2Smart For Life 28TM 29 Makes Debut on BJs com 59203 3Little Company of Mary Proceeds with Plans to Transform Hospital Campus 59199 1Little Company of Mary Proceeds with Plans to Transform Hospital Campus 59199 2Strategic Alliance Between Televisa and Genomma Lab 59195 1
...ntain codeine may be risky for some,breastfeeding ...y of Western Ontario, and the Hospital for Sick Ch...on Koren published research in the journal, Clini...at the codeine used in some pain relief drugs can ...nfants when ingested by some breastfeeding mothers...
...genetic code of a simple saltwater creature could ...nes function in humans and other species. , A stu...aks down the genetic code of Trichoplax , a simpl...in the world, even in the common household aquariu...x , genes that are also found in other animals - o...
...ide algae, Karenia brevis, costs approximately $20...t of Florida alone. Scientists at the Georgia Inst...educe the levels of the red tide,s toxicity to ani...s toxicity to other algae as well. If scientists c...y of red tide, they could reduce the vast amount o...
Other Biology News:Codeine not safe for all breastfeeding moms and their babies 2Genome of saltwater creature could aid understanding of gene grouping 2Biologists find diatom to reduce red tide's toxicity 2Biologists find diatom to reduce red tide's toxicity 3
Gey's Balanced Salt Solution (GBSS) from Sigma-Aldrich
...cations to the original formulas in efforts to pro...y an important role in tissue,culture. A salt solu...tic balance in the medium and to provide the cells...luable today as when it was first developed a cent...
Ellman's Reagent from Cayman Chemical
Synergy HT Multi-Detection Microplate Reader from BioTek Instruments
Biology Products: